Edwards Lifesciences
Edwards Lifesciences Corporation (NYSE: EW) develops and sells medical technologies for structural heart disease, serving patients through products used by cardiac surgeons and interventional cardiologists, as well as hospitals and other health care providers. Its portfolio spans transcatheter aortic valve replacement… From the company’s description.
In fiscal 2025, Edwards Lifesciences reported revenue of $6.07B, up 11.5% from fiscal 2024, and net income of $1.07B. Its operating margin was 20.8%, and operations generated $1.60B in cash. Over the twelve months to Jun 30, 2026, revenue was $6.51B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Edwards Lifesciences does
In the company’s own words
Edwards Lifesciences Corporation (NYSE: EW) develops and sells medical technologies for structural heart disease, serving patients through products used by cardiac surgeons and interventional cardiologists, as well as hospitals and other health care providers. Its portfolio spans transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart products. TAVR includes the SAPIEN family of valves and represented 74% of 2025 net sales; TMTT includes PASCAL, EVOQUE and SAPIEN M3 systems and represented 9%; surgical products include tissue heart valves and annuloplasty rings and represented 17%. The company sells in approximately 100 countries through direct sales forces and independent distributors, with 58% of 2025 net sales from the United States. Edwards Lifesciences reported approximately 16,000 employees worldwide as of December 31, 2025. Its website is www.edwards.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1099800
- SIC
- 3842
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Edwards Lifesciences — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Edwards Lifesciences’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Edwards Lifesciences’s bonds, as funds hold them
Funds report holding 1 issues of Edwards Lifesciences’s debt, $138.06M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.30%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Edwards Lifesciences and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Edwards Lifesciences's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Edwards Lifesciences's last four quarterly filings that the numbers alone won't show?”